Entera Bio annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Entera Bio Stock-Based Compensation Growth & History (ENTX)
Entera Bio's stock-based compensation was $2.8M for fiscal 2025.
View full Entera Bio company overviewEntera Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.8M | $194,000 | +7.59% |
| 2024 | 2024-12-31 | $2.6M | $867,000 | +51.33% |
| 2023 | 2023-12-31 | $1.7M | −$558,000 | −24.83% |
| 2022 | 2022-12-31 | $2.2M | $386,000 | +20.74% |
| 2021 | 2021-12-31 | $1.9M | $960,000 | +106.55% |
| 2020 | 2020-12-31 | $901,000 | −$999,000 | −52.58% |
| 2019 | 2019-12-31 | $1.9M | $1.9M | +169089.67% |
| 2018 | 2018-12-31 | $1,123 | −$4.9M | −99.98% |
| 2017 | 2017-12-31 | $4.9M | $3.4M | +227.85% |
| 2016 | 2016-12-31 | $1.5M | — | — |
Entera Bio quarterly stock-based compensation
Q2.19
Q2.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $624,000 | $115,000 | +22.59% |
| Q1 2026 | 2026-03-31 | $672,000 | $68,000 | +11.26% |
| Q4 2025 | 2025-12-31 | $710,000 | $144,000 | +25.44% |
| Q3 2025 | 2025-09-30 | $927,000 | −$1,000 | −0.11% |
| Q2 2025 | 2025-06-30 | $509,000 | −$89,000 | −14.88% |
| Q1 2025 | 2025-03-31 | $604,000 | $140,000 | +30.17% |
| Q4 2024 | 2024-12-31 | $566,000 | $248,000 | +77.99% |
| Q3 2024 | 2024-09-30 | $928,000 | $545,000 | +142.30% |
| Q2 2024 | 2024-06-30 | $598,000 | $126,000 | +26.69% |
| Q1 2024 | 2024-03-31 | $464,000 | −$52,000 | −10.08% |
| Q4 2023 | 2023-12-31 | $318,000 | −$159,000 | −33.33% |
| Q3 2023 | 2023-09-30 | $383,000 | $273,000 | +248.18% |
| Q2 2023 | 2023-06-30 | $472,000 | −$224,000 | −32.18% |
| Q1 2023 | 2023-03-31 | $516,000 | −$448,000 | −46.47% |
| Q4 2022 | 2022-12-31 | $477,000 | $109,000 | +29.62% |
| Q3 2022 | 2022-09-30 | $110,000 | −$518,000 | −82.48% |
| Q2 2022 | 2022-06-30 | $696,000 | $158,000 | +29.37% |
| Q1 2022 | 2022-03-31 | $964,000 | $637,000 | +194.80% |
| Q4 2021 | 2021-12-31 | $368,000 | — | — |
| Q3 2021 | 2021-09-30 | $628,000 | — | — |
| Q2 2021 | 2021-06-30 | $538,000 | $134,000 | +33.17% |
| Q1 2021 | 2021-03-31 | $327,000 | — | — |
| Q2 2020 | 2020-06-30 | $404,000 | $258,000 | +176.71% |
| Q2 2019 | 2019-06-30 | $146,000 | — | — |
Entera Bio stock-based compensation trends
Over the last five fiscal years, Entera Bio's stock-based compensation increased from $901,000 to $2.8M, a change of $1.8M. The latest reported quarter, Q2 2026, shows $624,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entera Bio source filings ↗